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Introduction
rangement of lobular architecture and fibrosis (10) . ™ Λ x , . « ., r . ,. . Liver fat-storing cells, referred to s vitamin A-containPlatelet-denved growth factor is a glyc protem con- (5, 6) , smooth muscle cells (7) and glial cells (8) in «>genesis (11) (12) (13) . Recent studies have shown that vitro. Therefore, human platelet-derived growth factor is platelet-derived growth factor and thrombocyte lysate thought to participate in wound healing and the develop-promote proliferation of cultured fat-storing cells and ment of arteriosclerosis in vivo (9) . On the other hand, stimulate synthesis of extracellular matrix, suggesting chronic liver diseases, including chronic hepatitis and the participation of platelet-derived growth factor in filiver cirrhosis, are characterized by destruction and de-brosis of the liver (14) (15) (16) (17) . Thrombocytopenia, which is frequently seen in chronic liver diseases, has been attributed to hypersplenism (10) . Stein & Harker reported that the life-span of platelets in the peripheral circulation and Ihe nuniber of platelets in chronic liver diseases are decreased, and that the platelets are consumed in the liver (18) . We previously reported that the amount of platelet-derived growth factor in the serum of patients with idiopathic thrombocytopenic purpura was lovver than that in control subjects, and that it correlated positively with the peripheral blood platelet count. Platelet-derived growth factor released from l O 9 platelets in patients with idiopathic thrombocytopenic purpura was not different from that in control subjects (19) . In this study, we measured the platelet-derived growth factor released from platelets in patients with chronic liver diseases, and found that it was increased and correlated with the severity of disease.
Materials and Methods

Subjects and sample preparation
The subjects studied consisted of 7 healthy volunteers (4 males and 3 females: 61 ± 9 years; mean ± SD) and 10 patients with chronic liver disease (chronic hepatitis and/or liver cirrhosis; 7 males and 3 females; 62 ± 8 years). Chronic liver disease was diagnosed on the basis of laboratory biochemical tests including serum levels of aspartate aminotransferase, alanine amlnotransferase, lbumin, globulin, total bilirubin and pseudocholinesterase, prothrombin time, indocyanine green clearance, Serologie tests for hepatitis viruses (hepatitis B virus antigen and hepatitis C virus antibody), and by imaging including ultrasonography, computed tomography, magnetic resonance imaging, radioisotope scanning, and angiography. Indocyanine green clearance was determined by calculation of the indocyanine green retention in the serum 15 min after intravenous injection of indocyanine green at a dose of 0.5 mg/kg body weight. Hepatitis C virus antibody was examined by enzymelinked immunosorbent assay (20) . None of the subjects had been administered any drugs that would affect platelet fiinction. Blood samples were obtained from these subjects in the rnoming after an ovemight fast. Serum samples were prepared by allowing 5 ml of blood to clot in a glass tube at room teji^perature for 2 h followed by Separation of serum by centrifug tion at 1000g for 10 min. Platelet-poor plasma was obtained from blood collected in a plastic syringe containing 4 mmol/1 EDTA and centrifuged at 12000g for 10 min at 4 °C. All these samples were stored at -20 °C for later analysis. The content of platelet-derived growth faetor did not increase on Standing for more than 2 h or by adding 2 μιηοΐ/ΐ adenosine diphosphate.
Platelet-derived growth factor determination
The platelet-derived growth factor concentration was measured using double^step competitive radioimmunoassay (RIA) kit (Amersham Co., Bucks, UK). In the RIA the following were used: platelet-derived growth factor B-chain homodimer (c-sis recombinant) labelled with 125 I s a tracer, platelet-derived growth factor B-chain homodimer (c-sis recombinant) s a Standard, a goat antl· human platelet-derived growth factor polyclonal antibody for the first antibody, and donkey anti-sheep antiserum in phosphate-buffered saline with gelatin and 10% polyethylene glycol for the second antibody. The r nge of this assay is 0.45-60 μg/l.
Statistical analysis
Statistical analysis was perfonned using the Wilcoxon rank sum test and correlations were calculated by Spearman's rank test. results of laboratory biochemical tests and diagnostic imaging, cases 1-5 and 7-10 were diagnosed s having liver cirrhosis and case 6 was diagnosed s having chronic hepatitis. In all the patients, chronic liver disease was due to viral hepatitis; hepatitis B in case 6 and hepatitis C in the other cases. The mean platelet count in the peripheral blood of patients with chronic liver disease, which was 98 ± 51 X 10 9 /1 (mean ± SD), was significantly (p < 0.01) lower than that of the control subjects, which was 211 ± 42 X 10 9 /1.
Results
In patients with chronic liver disease, the mean serum platelet-derived growth factor concentration was 4.6 ±1.8 μg/l (r nge 2.5-9.0 μg/l); it did not differ significantly from that in the control subjects, which was 5.0 ± 1.7 μg/l (r nge 1.9-7.5 μg/l) ( fig. la) . The serum platelet-derived growth factor concentration mainly reflects the amount of platelet-derived growth factor released from platelets, because the plasma platelet-derived growth factor concentrations of all the subjects studied were below the detection limit (< 0.45 μg/l). The amount of platelet-derived growth factor released from platelets was calculated s follows: the serum platelet-derived growth factor concentration was cor- rected for the haematocrit, divided by the peripheral blood platelet count, and expressed s ng platelet-derived'growth factor per l O 9 platelets. The mean amount of platelet-derived growth factor released from the platelets in patients with chronic liver disease, which was 33 ± 11 ng/10 9 cells, was significantly (p < 0.01) higher than that in the control subjects, which was 14 ± 5 ng/10 9 cells (fig. Ib) .
The amount of platelet-derived growth factor released from l O 9 platelets correlated inversely with the peripheral blood platelet count (r = -0.87, p < 0.01) and serum concentration of pseudocholinesterase activity (r = -0.65, p < 0.01), and correlated positively (r = 0.91, p < 0.01) with the percent retention of indocyanine green, in all the subjects studied. There was a negative correlation (r = -0.87, p < 0.01) between the peripheral blood platelet count and the percent retention of indocyanine green in the patients with chronic liver disease.
Discussion
We previously reported that the mean serum plateletderived growth factor concentration was significantly decreased in patients with idiopathic thrombocytopenic purpura, and that there was a significant positive correlation between blood platelet count and serum plateletderived growth factor concentration in the combined group of control subjects and patients with idiopathic thrombocytopenic purpura (19) . Platelet-derived growth factor is a local factor, and the clearance rate of plateletderived growth factor in the circulation in vivo is very rapid (21) . The concentrations of platelet-derived growth factor in plasma of all normal subjects and in patients with idiopathic thrombocytopenic purpura or chronic liver disease were below the detection limit. The concentrations of platelet-derived growth factor in serum were higher than those in ADP-stimulated plasma (22) . These obseryations suggest that the serum plateletderived growth factor level reflects mainly the amount of platelet-derived growth factor releasable from platelets, and that the platelet-derived growth factor released from the platelets is apparently dependent on the platelet count in the peripheral blood in patients with idiopathic thrombocytopenic purpura and normal subjects» The amount of platelet-derived growth factor releasable from the sarne number of platelets was not significantly different between patients with idiopathic thrombocytopenic purpura and normal subjects.
In the present study, although the mean platelet count in peripheral blood was significantly lower in patients with chronic liver disease than that in the control subjects, the mean serum platelet-derived growth factor level in Eur. J. Clin. Chem. Clin. Bioehem. / VoJ. 32,1994 / No. l patients wilh chronic liver disease was not lower than that in control subjects (fig. l a) . Jorgensen et al. reportcd that the mean volume of platelets in patients with chronic liver disease was smaller than that in normal subjects (23) . These findings suggest that the amount of platelet-derived growth factor releasable from each platelet is increased and concentrated in patients with chronic liver disease. The mean amount of platelet-derived growth factor released from platelets in patients with chronic liver disease was significantly greater than that in control subjects (fig. Ib) . The value significantly correlated with indicators of liver function, such äs the serum concentration of pseudocholinesterase and the indocyanine green value in the combined group. Serum pseudocholinesterase activity and indocyanine green clearance rate are known to reflect liver function and are thought to be markers of the progression of liver cirrhosis (10) . In this study, we focussed on serum plateletderived growth factor for evaluation of the amount of platelet-derived growth factor released from platelets, instead of meäsuring the cellular content of platelet-derived growth factor from platelet lysate. Actually, the ratio of platelet-derived growth factor released from the aggregated platelets to cellular platelet-derived growth factor was 0.80 ± 0.20 (mean ± SD) in 4 healthy volunteers (data not shown). This observation suggests that the majority of cellular platelet-derived growth factor is released at the time of aggregation, and that measurement of serum platelet-derived growth factor reflects the cellular content of platelet-derived growth factor (cf. tab. 2). Moreover, serum platelet-derived growth factor values would reflect the amount of platelet-derived growth factor released from platelets during platelet aggregation at sites of inflammation in the liver in vivo. Although platelet-derived growth factor is known to bind to a 2 -macroglobulin (24) and other plasma proteins, the effect of these binding proteins on our assay System should be minimal, since the plasma levels of platelet-derived growth factor studied were all below the detection limit in our assay System. Thrombocytopenia is often seen in patients with chronic liver disease associated with portal hypertension and/or hypersplenism. The life-span of platelets is shortened and platelets are assumed to be consumed in the liver in chronic liver diseases (18) . Several types of in vivo studies have demonstrated that fat-storing cells play a central role in liver fibrogenesis (11 -13) . Recent studies have also shown that platelet-derived growth factor stimülates proliferation of cultured fafcstoring cells and synthesis of mätrix components by fat-storirig cells (14) (15) (16) (17) . However, the source of platelet-derived growth factor in liver fibrogenesis is unceftain. In patients with idiopathic pulmonary fibrosis, alveolar macrophages release a large amount of platelet-derived growth factor (25) . In chronic liver diseases, it is possible that activated macrophages, including Kupffer cells, and/or platelets, which accumulate in hepatic inflammation (18, 26) , release plateletd erived growth factor. These findings suggest that the large amount of platelet-derived growth factor released by platelet activation in patients with chronic liver disease may be involved in the pathophysiology of chronic liver diseases äs a locäl factor.
Further studies are requifed on the mechaiiism of increase of platelet-derived growth factor in platelets in patients with chronic liver disease, on whether plateletderived growth factor is released at inflammatory sites in the liver in chronic liver disease, and on whether or not platelet-derived growth factor aggravates the progression of chronic liver diseases in vivo. 
